Seijas-Amigo, J.; Mauriz-Montero, M.J.; Suarez-Artime, P.; Gayoso-Rey, M.; Reyes-SantÃas, F.; Estany-Gestal, A.; Casas-MartÃnez, A.; González-Freire, L.; Rodriguez-Vazquez, A.; Pérez-Rodriguez, N.;
et al. Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study. Diseases 2024, 12, 244.
https://doi.org/10.3390/diseases12100244
AMA Style
Seijas-Amigo J, Mauriz-Montero MJ, Suarez-Artime P, Gayoso-Rey M, Reyes-SantÃas F, Estany-Gestal A, Casas-MartÃnez A, González-Freire L, Rodriguez-Vazquez A, Pérez-Rodriguez N,
et al. Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study. Diseases. 2024; 12(10):244.
https://doi.org/10.3390/diseases12100244
Chicago/Turabian Style
Seijas-Amigo, José, Maria José Mauriz-Montero, Pedro Suarez-Artime, Mónica Gayoso-Rey, Francisco Reyes-SantÃas, Ana Estany-Gestal, Antonia Casas-MartÃnez, Lara González-Freire, Ana Rodriguez-Vazquez, Natalia Pérez-Rodriguez,
and et al. 2024. "Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study" Diseases 12, no. 10: 244.
https://doi.org/10.3390/diseases12100244
APA Style
Seijas-Amigo, J., Mauriz-Montero, M. J., Suarez-Artime, P., Gayoso-Rey, M., Reyes-SantÃas, F., Estany-Gestal, A., Casas-MartÃnez, A., González-Freire, L., Rodriguez-Vazquez, A., Pérez-Rodriguez, N., Villaverde-Piñeiro, L., Castro-Rubinos, C., Espino-Paisán, E., Cordova-Arevalo, O., Rodriguez-Penas, D., Cardeso-Paredes, B., Ribeiro-Ferreiro, M., RodrÃguez-Mañero, M., Cordero, A.,
... MEMOGAL Investigators.
(2024). Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study. Diseases, 12(10), 244.
https://doi.org/10.3390/diseases12100244